Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
Version 2 2024-06-06, 10:34Version 2 2024-06-06, 10:34
Version 1 2020-11-10, 08:15Version 1 2020-11-10, 08:15
journal contribution
posted on 2024-06-06, 10:34authored byT Khoo, Lan GaoLan Gao
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
History
Journal
Expert Review of Pharmacoeconomics and Outcomes Research